메뉴 건너뛰기




Volumn 38, Issue 1, 2013, Pages 23-26

Abiraterone (Zytiga), a novel agent for the management of castration-resistant prostate cancer

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ALBUMIN; ANDROGEN; DEXTROMETHORPHAN; DOCETAXEL; EPLERENONE; ESTROGEN; GONADORELIN AGONIST; KETOCONAZOLE; MINERALOCORTICOID; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

EID: 84872703900     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note
Times cited : (28)

References (23)
  • 2
    • 84856610514 scopus 로고    scopus 로고
    • National Cancer Institute, Available at:, Accessed June 18, 2012
    • National Cancer Institute. Clinical trials search results. Available at: www.cancer. gov/cancertopics/types/prostate. Accessed June 18, 2012.
    • Clinical trials search results
  • 3
    • 0034694678 scopus 로고    scopus 로고
    • Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals
    • Platz EA, Rimm EB, Willett WC, et al. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst 2000;92(24):2009-2017.
    • (2000) J Natl Cancer Inst , vol.92 , Issue.24 , pp. 2009-2017
    • Platz, E.A.1    Rimm, E.B.2    Willett, W.C.3
  • 4
    • 79958043675 scopus 로고    scopus 로고
    • (eds.), Bethesda, Md.: National Cancer Institute. Based on November 2011 SEER data submission. Updated August 20, Available at:, Accessed December 12, 2012
    • Howlader N, Noone AM, Krapcho M, et al. (eds.). SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesda, Md.: National Cancer Institute. Based on November 2011 SEER data submission. Updated August 20, 2012. Available at: http://seer.cancer. gov/csr/1975_2009_pops09. Accessed December 12, 2012.
    • (2012) SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations)
    • Howlader, N.1    Noone, A.M.2    Krapcho, M.3
  • 5
    • 0842311632 scopus 로고    scopus 로고
    • The androgen axis in recurrent prostate cancer
    • Mohler JI, Gregory CW, Ford OH III, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004; 10(2):440-448.
    • (2004) Clin Cancer Res , vol.10 , Issue.2 , pp. 440-448
    • Mohler, J.I.1    Gregory, C.W.2    Ford III, O.H.3
  • 7
    • 51449087794 scopus 로고    scopus 로고
    • Targeting the androgen receptor pathway in prostate cancer
    • Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008;8(4):440-448.
    • (2008) Curr Opin Pharmacol , vol.8 , Issue.4 , pp. 440-448
    • Chen, Y.1    Sawyers, C.L.2    Scher, H.I.3
  • 9
    • 79957497548 scopus 로고    scopus 로고
    • Expanding treatment options for metastatic prostate cancer
    • Antonarakis ES, Eisneberger MA. Expanding treatment options for metastatic prostate cancer. N Engl J Med 2011; 364(21):2055-2058.
    • (2011) N Engl J Med , vol.364 , Issue.21 , pp. 2055-2058
    • Antonarakis, E.S.1    Eisneberger, M.A.2
  • 10
    • 4744366279 scopus 로고    scopus 로고
    • Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
    • Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512.
    • (2004) N Engl J Med , vol.351 , pp. 1502-1512
    • Tannock, I.F.1    de Wit, R.2    Berry, W.R.3
  • 11
    • 77953421580 scopus 로고    scopus 로고
    • Clinical Practice Guidelines: Prostate Cancer, version 3.2012
    • National Comprehensive Cancer Network. Clinical Practice Guidelines: Prostate Cancer, version 3.2012.
    • National Comprehensive Cancer Network
  • 12
    • 0842311632 scopus 로고    scopus 로고
    • The androgen axis in recurrent prostate cancer
    • Mohler JI, Gregory CW, Ford OH III, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004; 10(2):440-448.
    • (2004) Clin Cancer Res , vol.10 , Issue.2 , pp. 440-448
    • Mohler, J.I.1    Gregory, C.W.2    Ford III, O.H.3
  • 14
    • 80052827038 scopus 로고    scopus 로고
    • Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: Induction of steroidogenesis and androgen receptor splice variants
    • Mostaghel EA, Marck BT, Plymate SR, et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: Induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 2011;17:5913-5925.
    • (2011) Clin Cancer Res , vol.17 , pp. 5913-5925
    • Mostaghel, E.A.1    Marck, B.T.2    Plymate, S.R.3
  • 16
    • 77951523950 scopus 로고    scopus 로고
    • Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy
    • Ryan CJ, Smith MR, Fong L, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010;28(9):1481-1488.
    • (2010) J Clin Oncol , vol.28 , Issue.9 , pp. 1481-1488
    • Ryan, C.J.1    Smith, M.R.2    Fong, L.3
  • 17
    • 84863791271 scopus 로고    scopus 로고
    • Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men
    • Acharya M, Bernard A, Gonzalez M, et al. Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men. Cancer Chemother Pharmacol 2012;69(6):1583-1590.
    • (2012) Cancer Chemother Pharmacol , vol.69 , Issue.6 , pp. 1583-1590
    • Acharya, M.1    Bernard, A.2    Gonzalez, M.3
  • 18
    • 77951518711 scopus 로고    scopus 로고
    • Significant and sustained antitumor activity in post-docetaxel, castrationresistant prostate cancer with the CYP17 inhibitor abiraterone acetate
    • Reid AHM, Attard G, Danila DC, et al. Significant and sustained antitumor activity in post-docetaxel, castrationresistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010;28:1489-1495.
    • (2010) J Clin Oncol , vol.28 , pp. 1489-1495
    • Reid, A.H.M.1    Attard, G.2    Danila, D.C.3
  • 19
    • 77951591066 scopus 로고    scopus 로고
    • Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel treated castration-resistant prostate cancer
    • Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel treated castration-resistant prostate cancer. J Clin Oncol 2010;28:1496-1501.
    • (2010) J Clin Oncol , vol.28 , pp. 1496-1501
    • Danila, D.C.1    Morris, M.J.2    de Bono, J.S.3
  • 20
    • 79957443342 scopus 로고    scopus 로고
    • Abiraterone and increased survival in metastatic prostate cancer
    • De Bono JS, Logothetis CJ, Molin A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
    • (2011) N Engl J Med , vol.364 , pp. 1995-2005
    • de Bono, J.S.1    Logothetis, C.J.2    Molin, A.3
  • 21
    • 0020396015 scopus 로고
    • Toxicity and response criteria of the Eastern Cooperative Oncology Group
    • Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
    • (1982) Am J Clin Oncol , vol.5 , pp. 649-655
    • Oken, M.M.1    Creech, R.H.2    Tormey, D.C.3
  • 22
    • 0032747375 scopus 로고    scopus 로고
    • Eligibility and response guidelines for phase II clinical trials in androgenindependent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group
    • Bubley GJ, Carducci M, Dahut W, et al: Eligibility and response guidelines for phase II clinical trials in androgenindependent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17: 3461-3467.
    • (1999) J Clin Oncol , vol.17 , pp. 3461-3467
    • Bubley, G.J.1    Carducci, M.2    Dahut, W.3
  • 23
    • 84871048865 scopus 로고    scopus 로고
    • Available at:, Accessed June 29, 2012
    • Red Book online®. Available at: www. thomsonhc.com. Accessed June 29, 2012.
    • Red Book online®


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.